Page 46 - 2025中醫藥與天然藥物聯合學術研討會-中醫藥與天然藥物的挑戰Ｘ機遇與未來大會手冊

鄒倫 教授 Lun Kelvin Tsou, PhD

◼ Position/Affiliation/E-mail
Photo
Position/Affiliation:
(Ratio 4X3)
Investigator and Associate Director, Institute of Biotechnology and
Pharmaceutical Research (IBPR), National Health Research Institutes
(NHRI), Miaoli, Taiwan.
E-mail: kelvintsou@nhri.edu.tw

◼ Biography
Dr. Tsou earned his Bachelor of Science degree from the University of North Carolina at
Chapel Hill, where his research focused on cation-pi interactions in protein folding. He later

completed his Ph.D. in Chemistry at Yale University in 2007 under Professor Andrew D.
Hamilton, designing biomimetic inhibitors to disrupt disease-related protein-protein
interactions. His postdoctoral fellowship at The Rockefeller University with Dr. Howard C.
Hang explored post-translational modifications in host-pathogen interactions. Since joining

IBPR at Taiwan’s NHRI in 2012, Dr. Tsou has led several drug discovery initiatives. As a
project leader, he pioneered the development of first-in-class small molecule-drug conjugates
(SMDCs) for cancer therapy, including DBPR115, the first Taiwan-developed SMDC to enter
clinical trials by earning FDA approvals in Taiwan and the U.S. in 2021. With another

successful technology transfer in 2021, his team advanced DBPR186, a mertansine-based
SMDC, into preclinical studies. Moreover, DBPR376, a peptide-drug conjugate, was also tech-
transferred in 2025. Beyond SMDCs, Dr. Tsou collaborated with Dr. Lee-Ming Chuang’s team
at National Taiwan University and developed novel PTGR2 inhibitors for diabetes. Addressing

challenges in marine-derived drug development, he partnered with Dr. Ping-Jyun Sung and Dr.
Mingzi Zhang’s group to employ late-stage modification strategies, resulting in GHN105: the
first orally bioavailable, covalent STING inhibitor derived from natural products, marking a
breakthrough in targeting “undruggable” proteins. Through interdisciplinary collaborations and

sustained innovation, Dr. Tsou’s lab continues to translate cutting-edge science into
transformative therapies, solidifying its role in advancing novel treatments for global health
challenges.

24